| 1OSF | A:196-223 | HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N-DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN |
| 1UY6 | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UY7 | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UY8 | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY-BENZYL)-9H-PURIN-6YLAMINE |
| 1UY9 | A:196-224 | HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE |
| 1UYC | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UYD | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE |
| 1UYE | A:196-224 | HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE |
| 1UYF | A:196-224 | HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5-TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE |
| 1UYG | A:196-224 | HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYH | A:196-224 | HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYI | A:196-224 | HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2-FLUORO-9-PENT-9H-PURIN-6-YLAMINE |
| 1UYK | A:196-224 | HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE |
| 1UYL | A:196-224 | STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR BINDING TO HSP90 ISOFORMS |
| 1YC1 | A:196-224 | CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YC3 | A:196-223 | CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YC4 | A:196-224 | CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED WITH DIHYDROXYPHENYLPYRAZOLES |
| 1YER | A:196-223 | HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION |
| 1YES | A:196-223 | HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION |
| 1YET | A:196-223 | GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN |
| 2JJC | A:196-223 | HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT |
| 2K5B | A:196-223 | HUMAN CDC37-HSP90 DOCKING MODEL BASED ON NMR |
| 2QF6 | D:196-223; D:196-223; D:196-223; D:196-223 | HSP90 COMPLEXED WITH A56322 |
| 2QFO | B:196-223; B:196-223 | HSP90 COMPLEXED WITH A143571 AND A516383 |
| 2QG0 | B:196-223; B:196-223 | HSP90 COMPLEXED WITH A943037 |
| 2QG2 | A:196-223 | HSP90 COMPLEXED WITH A917985 |
| 2UWD | A:196-224 | INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE ANALOGS |
| 2VCI | A:196-224 | 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| 2VCJ | A:196-224 | 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| 2WI1 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI2 | B:196-224; B:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI3 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI4 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI5 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI6 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI7 | A:196-224 | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2XAB | B:196-224; B:196-224 | STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND |
| 2XDK | A:196-225 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDL | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDS | A:196-223 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDU | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDX | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHR | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHT | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHX | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJG | A:196-223 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJJ | B:196-224; B:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJX | A:196-231 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XK2 | A:196-224 | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2YE2 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE3 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE4 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE5 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE6 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE7 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE8 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE9 | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEA | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEB | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEC | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YED | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEE | A:196-223 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEF | A:196-226 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEG | B:196-224; B:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEH | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEI | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEJ | A:196-224 | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 3K97 | A:196-225 | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH 4-CHLORO-6-{[(2R)-2-(2-METHYLPHENYL)PYRROLIDIN-1-YL]CARBONYL}BENZENE-1,3-DIOL |
| 3K98 | B:196-225; B:196-225 | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH (1R)-2-(5-CHLORO-2, 4-DIHYDROXYBENZOYL)-N-ETHYLISOINDOLINE-1-CARBOXAMIDE |
| 3K99 | D:196-225; D:196-225; D:196-225; D:196-225 | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH 4-(1,3-DIHYDRO-2H-ISOINDOL-2-YLCARBONYL)BENZENE-1,3-DIOL |
| 3MNR | P:196-224 | CRYSTAL STRUCTURE OF BENZAMIDE SNX-1321 BOUND TO HSP90 |
| 3Q6M | C:294-697; C:294-697; C:294-697 | CRYSTAL STRUCTURE OF HUMAN MC-HSP90 IN C2221 SPACE GROUP |
| 3QTF | A:196-223 | DESIGN AND SAR OF MACROCYCLIC HSP90 INHIBITORS WITH INCREASED METABOLIC STABILITY AND POTENT CELL-PROLIFERATION ACTIVITY |
| 3R4M | A:196-225 | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4N | B:196-225; B:196-225 | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4O | B:196-225; B:196-225 | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R4P | B:196-225; B:196-225 | OPTIMIZATION OF POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE PYRROLODINOPYRIMIDINE-CONTAINING INHIBITORS OF HEAT SHOCK PROTEIN 90. IDENTIFICATION OF DEVELOPMENT CANDIDATE 2-AMINO-4-{4-CHLORO-2-[2-(4-FLUORO-1H-PYRAZOL-1-YL)ETHOXY]-6-METHYLPHENYL}-N-(2,2-DIFLUOROPROPYL)-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE |
| 3R92 | A:196-224 | DISCOVERY OF A MACROCYCLIC O-AMINOBENZAMIDE HSP90 INHIBITOR WITH HETEROCYCLIC TETHER THAT SHOWS EXTENDED BIOMARKER ACTIVITY AND IN VIVO EFFICACY IN A MOUSE XENOGRAFT MODEL. |
| 3RLP | B:196-225; B:196-225 | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-6-METHYLPYRIMIDIN-2-AMINE |
| 3RLQ | B:196-225; B:196-225 | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-2-METHYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5- CARBONITRILE |
| 3RLR | B:196-225; B:196-225 | CO-CRYSTAL STRUCTURE OF THE HSP90 ATP BINDING DOMAIN IN COMPLEX WITH 4-(2,4-DICHLORO-5-METHOXYPHENYL)-2,6-DIMETHYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONITRILE |
| 1UYM | A:196-226 | HUMAN HSP90-BETA WITH PU3 (9-BUTYL-8(3,4,5-TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE) |
| 3NMQ | A:196-226 | HSP90B N-TERMINAL DOMAIN IN COMPLEX WITH EC44, A PYRROLO-PYRIMIDINE METHOXYPYRIDINE INHIBITOR |
| 3PRY | C:285-543; C:285-543; C:285-543 | CRYSTAL STRUCTURE OF THE MIDDLE DOMAIN OF HUMAN HSP90-BETA REFINED AT 2.3 A RESOLUTION |
)
)